OR WAIT 15 SECS
March 27, 2016
Bridge Medicines (New York, NY), a recently established drug discovery company, announced the appointment of William J. Polvino, M.D., as chief executive officer. Kathleen Metters, Ph.D., who served as the interim CEO upon the establishment of the company in October 2016, will continue to have an operating role within the organization, and will chair the Scientific Advisory Board. Most recently, Dr. Polvino was president and chief executive officer of Veloxis Pharmaceuticals. Prior to this he served as president and CEO of Helsinn Therapeutics (formerly Sapphire Therapeutics). Dr. Polvino has also held executive and senior-level positions in drug development at Merck, Wyeth, and Theravance.